The substrate

Intelligence you can defend.

Decision-grade intelligence requires decision-grade provenance. Here is how the LAI substrate is scoped, classified, and sourced.

The boundary

What counts as a long-acting injectable.

The scope is an explicit, documented editorial decision — reviewed as the field moves, never a keyword match. A molecule is in scope when its long duration is engineered — obtained from an identifiable delivery or half-life-extension technology, by an injectable route — reaching well beyond the molecule’s own unmodified pharmacology. Some long-acting injectables have an immediate-release sibling; many were designed as long-acting from the start. What defines scope is the technology behind the duration, not a comparison to another product. Where the line sits is a decision we document, and revisit.

The technology map

The technology, classified.

Long-acting injection is, first, an engineering question: how a molecule is made to last. That is why the technology taxonomy is the core of Vectora. We separate what extends the action from what carries it, on orthogonal axes that combine — an asset can be a physical depot, of a given matrix, on a given route.

Drug delivery systems — DDS

Physical release

MicrosphereNanocrystalNanoparticleIn-situ depotGel depotImplantLiposomeOil depot

Chemical release

Prodrug (ester, amide)Cleavable conjugate

Matrix material

PolymerLipidHydrogelInorganic

Half-life extension — HLE

Mechanism

PEGylationLipidationAlbumin-bindingFc-fusionGlyco-engineeringProtein-fusion extender

Every asset is placed on these axes — and where a mechanism is a named, proprietary platform, it is tracked as such, not flattened into a generic label.

Inputs & cadence

Public inputs, monitored year-round.

The raw material is public — regulatory bodies (FDA, EMA), clinical registries, the scientific literature, corporate disclosures — and it is monitored continuously, so the picture tracks the field as it moves, not a yearly snapshot. What turns those scattered signals into intelligence is proprietary: the ontology, the delivery-technology taxonomy, and the curation decisions that resolve every entity into a single, queryable whole.

Provenance

Where each value comes from.

Regulatory facts, linked to source

On every product, the FDA and EMA facts carry a link to their official label (DailyMed, EMA). Open the document and read it yourself — the source is one click away.

Everything else, curated to the ontology

Delivery technology, release families, molecular properties, targets and more are captured from public sources and resolved into Vectora’s ontology — consistent and comparable across the whole scope.

Curation

Governed by domain expertise.

The ontology, the delivery-technology taxonomy, and the scope are defined and maintained by an analyst with eleven years in pharmaceutical competitive intelligence, three of them in Long-Acting Injectables. Those editorial decisions — what qualifies, how a technology is classified — are the work no generalist database has done for this niche.